BMS, Celgene shareholders approve acquisition

Shareholders from both BMS and Celgene voted Friday to approve the pharma's acquisition of the biotech for $74 billion in a cash and stock deal.

While the deal had its share of opposition and support, the companies said Friday that over 75% of Bristol-Myers Squibb Co. (NYSE:BMY) and 70% of Celgene Corp. (NASDAQ:CELG) shareholder votes were in favor of the acquisition (see "BMS Shareholder Opposition of Celgene Takeout Builds"; "Proxy Firms Back BMS in Celgene Takeout")...